July 19, 2022
July 19, 2022 –
Incyte's OpzeluraTM (ruxolitinib) cream has been approved for the topical treatment of nonsegmental vitiligo in patients who are at least 12 years old.
July 15, 2022
July 15, 2022 –
ZonisadeTM (zonisamide oral suspension) has received FDA approval to provide adjunctive therapy for the treatment of partial onset seizures in patients
July 14, 2022
July 14, 2022 –
Pfizer’s Xalkori® (crizotinib) has received a new indication to treat unresectable, recurrent,
or refractory ALK-positive inflammatory yofibroblastic
July 14, 2022
July 14, 2022 –
Diacomit® (stiripentol) is now indicated for use with clobazam to treat seizures associated with Dravet syndrome in patients at least six months of age and
July 13, 2022
July 13, 2022 –
The FDA has granted emergency use authorization to Novavax’s COVID-19 vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus in adults.
July 8, 2022
July 8, 2022 –
Krystexxa® (pegloticase – Horizon Therapeutics) has received an expanded indication for co-administration with methotrexate to treat chronic gout
July 8, 2022
July 8, 2022 –
Comirnaty® (COVID-19 vaccine, mRNA – Pfizer and BioNTech) is now FDA approved for use in adolescents who are 12-15 years old. This age group
July 6, 2022
July 6, 2022 –
Mylan Pharmaceuticals has recalled one batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3mL prefilled pens. The product